Amgen continues M&A flurry with $3.7bn deal

08-08-2022

Staff Writer

Amgen continues M&A flurry with $3.7bn deal

Marlon Trottmann / Shutterstock.com

Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics | Deal includes acquisition of Tavneos (avacopan) | Spate of acquisitions follows increased competition.


Amgen, ChemoCentryx, M&A, mergers and acquisitions, patent cliffs, autoimmune diseases, inflammatory disorders, cancer, Tavneos

LSIPR